金属对金属全髋关节置换术中不良局部组织反应的临床表现:一项MRI研究
该回顾性研究基于前瞻性国际多中心ASR髋关节系统队列,分析327例单侧患者,评估症状与MARS-MRI上不良局部组织反应(ALTR)的关联及血金属离子阈值。结果发现,在ASR金属对金属全髋关节置换术(MoM THA)中,症状是ALTR的危险因素(OR 2.9,p=0.007),且钴阈值3.2 ppb与ALTR风险增加相关;在ASR MoM髋关节表面置换术(HRA)中,症状与ALTR无关联,钴阈值2.9 ppb提示ALTR。
要点
- 在ASR MoM THA患者中,症状与ALTR存在相关(OR 2.9,p=0.007)。
- ASR MoM THA的钴阈值为3.2 ppb(灵敏度68%,特异度71%)。
- ASR MoM HRA的钴阈值为2.9 ppb(灵敏度79%,特异度69%)。
核心结论
- 在ASR MoM THA患者中,症状与ALTR存在相关,且钴离子水平与ALTR相关;在ASR MoM HRA患者中,症状与ALTR无关联,但钴离子水平与ALTR相关。
- 作者认为,基于症状和血金属离子水平可对MoM植入患者进行ALTR风险分层,并可用于筛查MoM HRA患者。
- 作者认为,MoM HRA随访方案中豁免无症状患者年度随访的做法不合理,因为无症状患者发生ALTR的可能性并不低于有症状患者。
研究设计与样本
- 本研究为回顾性研究,是对一项前瞻性、国际、多中心召回的Articular Surface Replacement(ASR)髋关节系统研究的二次分析。
- 共纳入来自6个国家16个中心的1721例患者,每年随访5年;本分析仅纳入两个中心中所有患者均常规接受MARS-MRI检查的单侧患者327例(占符合条件者的90%)。
- 从初次手术至入组访视的平均时间为7.5年(标准差3.5年)。
主要发现
- 在控制混杂变量后,ASR MoM THA患者中症状存在是ALTR的危险因素(OR 2.9;p=0.007)。
- 在ASR MoM THA伴ALTR的患者中,滑膜厚度与症状存在相关(p=0.030)。
- 在ASR MoM HRA患者中,症状与ALTR患病率或严重程度无关联。
- ASR MoM THA中钴阈值为3.2 ppb与ALTR风险增加相关(p<0.001;灵敏度68%;特异度71%)。
- ASR MoM HRA中钴阈值为2.9 ppb提示ALTR(p<0.001;灵敏度79%;特异度69%)。
关键数值与推荐
- ASR MoM THA:症状与ALTR相关(OR 2.9;p=0.007)。
- ASR MoM THA:钴阈值3.2 ppb(p<0.001;灵敏度68%;特异度71%)。
- ASR MoM HRA:钴阈值2.9 ppb(p<0.001;灵敏度79%;特异度69%)。
- MARS-MRI评估的读者内可重复性:组内相关系数=0.82;与肌骨放射科医生的一致性:κ系数=0.64。
临床怎么用
- 作者认为,当前研究识别的危险因素可用于对MoM植入患者进行ALTR风险分层。
- 作者认为,在ASR MoM THA中,症状与ALTR可能性增加相关,钴离子水平与ALTR相关;在ASR MoM HRA中,钴离子水平与ALTR相关。
- 作者认为,血金属离子水平可可靠地用于筛查MoM HRA患者;对于MoM THA患者,症状状态联合血金属离子水平可用于确定ALTR风险。
- 作者认为,MoM HRA随访方案中豁免无症状患者年度随访的做法不合理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adverse local tissue reaction (ALTR) is not only a prominent cause of metal-on-metal (MoM) implant revision, but may also compromise the result of revision surgery. Patients treated with MoM arthroplasty and subsequently revised as a result of ALTR have been shown to experience worse patient-reported outcomes, inferior survivorship, and more complications when compared with patients receiving MoM implants who were revised for reasons other than ALTR. There is conflicting evidence as to whether the presence of symptoms is associated with ALTR in patients with MoM implants. Blood metal ions are associated with ALTR, but a consensus on appropriate thresholds associated with ALTR risk is lacking. QUESTIONS/PURPOSES: (1) Was the presence of symptoms as measured by patient-reported outcome measures associated with ALTR presence and severity as noted on metal artifact reduction sequence (MARS)-MRI in patients treated with one design of MoM THA or hip resurfacing arthroplasty (HRA)? (2) Could reliable thresholds for blood metal ion levels be determined that were associated with ALTR presence on MARS-MRI? METHODS: This retrospective study presents a secondary analysis of data drawn from a prospective, international, multicenter study of the recalled Articular Surface Replacement (ASR) hip system. This larger study aims to identify risk factors for revision and provide followup guidelines for the many unrevised ASR patients. A total of 1721 patients were enrolled from 16 centers in six countries after the device was recalled and are followed annually for 5 years. In the present analysis, data from the enrollment visit (mean time from index surgery, 7.5 years; SD 3.5 years) were considered. Only patients from two centers conducting MARS-MRI on all patients regardless of clinical presentation as a standard of care were included to avoid selection bias. A total of 327 unilateral patients fulfilled our inclusion criteria (90% of those eligible). The level of symptoms was systematically determined using the Harris hip score and a visual analog scale for pain, and whole blood metal ion levels were collected from all patients. MARS-MRIs were analyzed by a single reader for ALTR presence (Anderson classification), diameter, and synovial thickness. A validation series of 35 MARS-MRIs indicated excellent intrareader reproducibility of the evaluations (intraclass correlation = 0.82) and substantial agreement (κ coefficient = 0.64) was achieved between the MARS-MRI reader and a musculoskeletal radiologist with > 10 years of experience with MARS-MRI. Binary logistic regression was used to determine variables independently associated with ALTR. Receiver operator characteristic curves were used to determine sensitive and specific cut points for cobalt and chromium. RESULTS: After controlling for confounding variables, presence of symptoms was determined to be a risk factor for ALTR (odds ratio, 2.9; p = 0.007) in patients treated with ASR MoM THA. Moreover, among patients undergoing ASR MoM THA with ALTR, synovial thickness correlated with symptomaticity (p = 0.030). For patients undergoing ASR MoM HRA, we found no association between symptoms and ALTR prevalence or severity. A cobalt cutoff of 3.2 parts per billion (ppb) was associated with increased risk of ALTR (p < 0.001; sensitivity, 68%; specificity, 71%) in ASR MoM THA. In patients with ASR MoM HRA, a cobalt threshold of 2.9 ppb was indicative of ALTR (p < 0.001; sensitivity, 79%; specificity, 69%). CONCLUSIONS: The risk factors identified in the current study may be used to stratify patients receiving MoM implants in terms of ALTR risk. We found that symptoms are associated with an increased likelihood of ALTR presence in ASR MoM THA and that cobalt ion level is associated with ALTR in ASR MoM THA as well as ASR MoM HRA. Importantly, MoM HRA followup protocols that exempt asymptomatic patients from annual followup are not justified because asymptomatic patients are no less likely to have ALTR than symptomatic patients. Blood metal ion levels may reliably be used to screen patients undergoing MoM HRA. For patients undergoing MoM THA, a combination of symptom state and blood metal ion levels may be used to determine ALTR risk. LEVEL OF EVIDENCE: Level III, diagnostic study.
引用
- Galea VP, Laaksonen I, Connelly JW, et al. What Is the Clinical Presentation of Adverse Local Tissue Reaction in Metal-on-metal Hip Arthroplasty? An MRI Study. Clin Orthop Relat Res. 2019. PMID: 30794223. doi:10.1097/CORR.0000000000000393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。